CONNECTA Therapeutics Spain

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability dataAwarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patientsCONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS programand boosted by the FRAXCURE project (co-funded by the European Union), CONNECTA is advancing CTH120 towards Phase II trials in adult and pediatric FXS populations.

CONNECTA's scalable neuroplasticity modulation platform has already yielded additional promising compounds that have shown potential in treating multiple CNS disorders. Preclinical models have demonstrated efficacy for FXS and Rett Syndrome, with the potential to address other high-value indications such as Down's syndrome, DiGeorge syndrome, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and neuropathic pain.

About FRAXCURE Project

FRAgile X syndrome Clinical trial: Unravelling the science behind this Rare disease in Europe | FRAXCURE | Project | Fact Sheet | HORIZON | CORDIS | European Commission. 

Funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

View original content:https://www.prnewswire.co.uk/news-releases/connecta-therapeutics-to-advance-cth120-into-phase-ii-pediatric-development-for-fragile-x-syndrome-with-eic-accelerator-support-302549587.html